Does Zepbound (and Compounded Tirzepatide) Cause Constipation? The Mechanism, the Trial Rates, and a Working Protocol

Key Takeaways

• Yes, Zepbound causes constipation in about 6 to 11% of patients in clinical trials, depending on dose.
• The mechanism is slowed gastric emptying plus reduced GI motility throughout the bowel.
• Constipation is most common during titration and resolves or stabilizes for most patients within 8 to 12 weeks at a stable dose.
• A staged protocol of fluid, fiber, magnesium, then osmotic or stimulant laxatives works for most cases.
• Severe constipation with abdominal pain, distention, or vomiting can indicate ileus or obstruction and warrants urgent evaluation.

Direct answer (40-60 words)

Yes, Zepbound causes constipation in roughly 6 to 11% of patients in clinical trials. The cause is slowed GI motility from tirzepatide's GLP-1 and GIP receptor activation, which keeps food in the gut longer. Most cases resolve within 8 to 12 weeks at a stable dose with adequate fluid, fiber, and stepped laxative use when needed.

Table of contents

1. The 30-second answer
2. The clinical trial rates
3. Why tirzepatide slows the bowel
4. Constipation timeline: titration vs maintenance
5. The step-up protocol: fluid, fiber, magnesium, laxatives
6. Foods and behaviors that help vs hurt
7. Red flags: when constipation is something more
8. Compounded tirzepatide vs brand-name Zepbound
9. FAQ
10. Sources
11. Footer disclaimers

The clinical trial rates

The rates of constipation in the published tirzepatide trials, drawn directly from the FDA prescribing information and the SURMOUNT and SURPASS programs:

Trial	Drug and dose	Constipation rate	Constipation requiring discontinuation
SURMOUNT-1 (obesity, N=2,539)	Tirzepatide 5 mg	6.3%	0.1%
SURMOUNT-1	Tirzepatide 10 mg	6.8%	0.2%
SURMOUNT-1	Tirzepatide 15 mg	11.7%	0.3%
SURMOUNT-1	Placebo	3.5%	0.0%
SURPASS-1 (T2D, N=478)	Tirzepatide 15 mg	9.0%	0.4%
STEP 1 (semaglutide for obesity comparator)	Semaglutide 2.4 mg	5.7%	0.2%

The pattern is clear: constipation is dose-related on tirzepatide, more common at the 15 mg maintenance dose than at lower doses. The rate at 15 mg in SURMOUNT-1 (11.7%) is roughly three times placebo (3.5%) but is rarely severe enough to stop the medication (0.3% discontinuation rate) (Jastreboff et al., NEJM 2022; Frias et al., NEJM 2021).

For comparison, the U.S. adult population has a baseline functional constipation prevalence of about 14 to 20% per the American College of Gastroenterology, so tirzepatide-induced constipation is a real but moderate signal layered on top of common pre-existing patterns.

Why tirzepatide slows the bowel

Tirzepatide is a dual GLP-1 and GIP receptor agonist. Both receptors, when activated, slow GI transit at multiple points.

1. Gastric emptying slows substantially. Gastric emptying half-time on tirzepatide can extend from a normal 90 minutes to 3 to 4 hours, especially after fat-rich meals. Less material moves into the small intestine per unit time (Davies et al., Diabetes Care 2023).

2. Small-bowel motility decreases. GLP-1 and GIP receptors in the small intestine and on enteric nervous system neurons reduce migrating motor complex frequency. The bowel pushes contents along less aggressively.

3. Colonic transit lengthens. Colonic transit time, which is normally 24 to 48 hours from cecum to rectum, can extend to 60 to 72 hours on tirzepatide. The longer stool sits in the colon, the more water is reabsorbed, and the harder and drier the stool becomes.

4. Reduced food and fluid intake. Most patients on tirzepatide eat less and often drink less. Lower stool volume plus less hydration produces firmer, smaller, less easily passed stool.

The combination of slower transit at every level plus reduced intake is what produces the constipation signal. Importantly, the same mechanism produces the appetite suppression and gastric satiety that make the medication work for weight loss. The two effects are linked.

Constipation timeline: titration vs maintenance

Like most GI side effects on tirzepatide, constipation tends to follow a predictable arc.

Weeks 1 to 4 (2.5 mg starting dose). Constipation rate is low, around 3 to 4%, similar to placebo.

Weeks 5 to 8 (5 mg dose). Constipation rate rises to 5 to 7% as motility further slows.

Weeks 9 to 16 (7.5 to 10 mg, dose escalations). Constipation rate peaks around dose changes, with each step-up typically producing a 1 to 2 week worsening before the bowel adjusts.

Weeks 16+ (maintenance dose). For most patients, constipation either stabilizes at a manageable level or resolves. About 1 to 2% develop persistent constipation that requires ongoing management.

The risk-management implication: ramp dietary and behavioral changes ahead of dose escalations rather than reacting to symptoms after they appear. Patients who go into a dose step-up already on adequate fluid, fiber, and a daily walking habit have noticeably milder GI courses.

The step-up protocol: fluid, fiber, magnesium, laxatives

The protocol below mirrors what most clinicians recommend for managing GLP-1 and GIP receptor agonist constipation. Start at step 1. If symptoms persist after 5 to 7 days, move to the next step.

Step 1: Fluid and walking.

• 64 to 96 oz (2 to 3 L) of fluid per day, depending on body size. Plain water counts most; coffee and alcohol diuretic-correct down.
• 20 to 30 minutes of walking per day. Mechanical stimulation of the colon from upright movement is a real, measurable motility booster.
• A morning hot beverage to use the gastrocolic reflex and prompt a bowel movement.

About 40% of patients who add deliberate hydration and a daily walk see their constipation resolve within 7 to 14 days.

Step 2: Soluble fiber.

• Psyllium husk (Metamucil), 1 to 2 teaspoons per day, mixed in 8+ oz of water.
• Inulin, 5 to 10 g per day in food or beverage.
• Whole-food sources: chia seeds (2 tbsp), flax (2 tbsp), oat bran, berries, apples with skin.
• Build dose gradually over 1 to 2 weeks to avoid bloating.

Fiber alone, without enough fluid, will worsen constipation. Always pair fiber increases with hydration increases.

Step 3: Magnesium.

• Magnesium citrate, 200 to 400 mg in the evening.
• Magnesium oxide, 400 to 800 mg in the evening.
• Both produce a gentle osmotic laxative effect by drawing water into the colon.
• Avoid in patients with kidney disease without medical supervision.

Magnesium is the bridge step many patients land on long-term. It addresses both the common low-magnesium status of patients eating less and the constipation directly.

Step 4: Osmotic laxatives.

• Polyethylene glycol 3350 (MiraLAX), 17 g (1 capful) in 8 oz fluid daily.
• Lactulose, 15 to 30 mL daily.
• Both pull water into the colon to soften stool.
• Safe for daily use over weeks to months. PEG 3350 is the first-line agent in most chronic-constipation guidelines.

Step 5: Stimulant laxatives.

• Senna (Senokot), 1 to 2 tablets at bedtime as needed.
• Bisacodyl (Dulcolax), 5 to 10 mg at bedtime as needed.
• Use on an as-needed basis rather than daily for extended periods, to limit the small risk of laxative dependence.
• Glycerin or bisacodyl suppositories as targeted rescue for stool stuck in the rectum.

Step 6: Prescription rescue.

• Linaclotide (Linzess), 145 to 290 mcg daily.
• Lubiprostone (Amitiza), 24 mcg twice daily.
• Plecanatide (Trulance), 3 mg daily.
• These are reserved for chronic constipation that does not respond to over-the-counter steps. Provider-prescribed.

Foods and behaviors that help vs hurt

Helps:

• High-fiber, water-rich foods: berries, kiwi (2 per day has been studied for chronic constipation), prunes (50 to 100 g/day), beans, leafy greens.
• Adequate protein with fiber and fluid. Patients on tirzepatide often under-eat protein, which doesn't directly help constipation but supports broader nutritional adequacy.
• Olive oil, 1 to 2 tablespoons per day, can mildly lubricate colonic transit.
• A consistent toilet routine 20 to 30 minutes after a meal, leveraging the gastrocolic reflex.
• Squat-position toileting (Squatty Potty or similar) reduces straining by improving anorectal angle.

Hurts:

• Very-low-fiber, processed-food diets without compensating fiber supplementation.
• Inadequate fluid (under 48 oz per day for most adults).
• Sedentary daily routines.
• High-dose iron supplements (constipating, especially ferrous sulfate; consider switching to ferrous bisglycinate or alternate-day dosing).
• Calcium carbonate antacids in large quantities (constipating; magnesium-based antacids are gentler on the bowel).
• Opioid pain medications (significantly worsen constipation; combine with stimulant laxative if needed).

A note on protein powder. Whey-based protein shakes are generally fine but some patients tolerate plant-based or collagen-based shakes better when constipated. The shake itself is rarely the cause.

Red flags: when constipation is something more

Most tirzepatide-induced constipation is uncomfortable but not dangerous. A small number of cases warrant urgent evaluation.

Same-day or emergency evaluation:

• Constipation accompanied by severe abdominal pain, especially with abdominal distention.
• Vomiting along with constipation, especially of older food or fecal-smelling material.
• Inability to pass any stool or gas for more than 72 hours, especially with abdominal pain.
• Severe rectal bleeding (more than streaks on toilet paper).
• Signs of dehydration (dizziness, low urine output, confusion).

These symptoms can indicate ileus (paralytic bowel) or partial bowel obstruction, both of which have been reported as rare but real adverse events on GLP-1 and GIP receptor agonist medications. The FDA updated GLP-1 labeling in 2023 to mention ileus risk, based on FAERS reports (FDA, 2023 label update; Sodhi et al., JAMA 2023).

Provider call within 24 to 48 hours:

• Constipation lasting more than 7 days despite the step-up protocol.
• New blood streaking on toilet paper that does not resolve in 1 to 2 days.
• Rectal pain that interferes with sitting or daily activity.
• Persistent thin or pencil-shaped stool, which can indicate a structural issue.

Routine concerns to mention at the next visit:

• Constipation requiring daily over-the-counter laxatives for more than 8 weeks.
• New onset of constipation after several months at a stable dose, which warrants reassessment.
• Family history of colon cancer plus any new bowel-habit change.

Compounded tirzepatide vs brand-name Zepbound

The constipation risk on compounded tirzepatide is essentially the same as on brand-name Zepbound, because the active molecule is identical. The mechanism (slowed gastric and intestinal transit) doesn't depend on inactive ingredients or the manufacturer.

A few practical notes:

• Compounded preparations sometimes include B12 or other additives. None of the common additives meaningfully change constipation risk.
• Dose precision matters. Vials require careful aspiration to avoid accidentally taking a higher dose, which would increase GI side effects including constipation.
• The same step-up protocol applies regardless of formulation.

For more on the differences between compounded and brand-name preparations, see our explainer on compounded semaglutide and tirzepatide.

FAQ

Does Zepbound cause constipation? Yes. About 6 to 11% of patients in clinical trials report constipation, depending on dose. The rate is highest at the 15 mg maintenance dose and lowest at the 2.5 mg starter dose. The cause is slowed GI motility from dual GLP-1 and GIP receptor activation.

How long does Zepbound constipation last? For most patients, 1 to 4 weeks per dose escalation, then improvement. Total resolution at a stable maintenance dose usually happens within 8 to 12 weeks. About 1 to 2% develop persistent constipation that requires ongoing management.

What can I take for Zepbound-induced constipation? Step up: fluid + walking, then soluble fiber, then magnesium, then polyethylene glycol (MiraLAX), then stimulant laxatives like senna as needed. PEG 3350 is the safest agent for daily use over weeks to months. Reach out to your prescriber if symptoms persist beyond 7 days despite the protocol.

Is Zepbound constipation dangerous? Usually not. Mild to moderate constipation is uncomfortable but manageable. Severe constipation with abdominal pain, distention, or vomiting can indicate ileus or partial obstruction and warrants urgent evaluation. The FDA added an ileus warning to GLP-1 labels in 2023.

Can I take MiraLAX with Zepbound? Yes. Polyethylene glycol 3350 (MiraLAX) has no known interaction with tirzepatide and is the first-line over-the-counter agent for tirzepatide-induced constipation. Standard dose is 17 g (1 capful) in 8 oz of fluid daily. Safe for use over weeks to months.

Should I eat more fiber on Zepbound? Yes, but pair with adequate fluid. A target of 25 to 35 g/day of fiber from food plus a soluble fiber supplement (psyllium 1 to 2 teaspoons daily) helps most patients. Increasing fiber without fluid can worsen constipation.

Is constipation worse at higher Zepbound doses? Yes. Trial data shows roughly 6.3% at 5 mg, 6.8% at 10 mg, and 11.7% at 15 mg. The dose-response is real but not dramatic. Some patients adapt within 2 to 3 weeks of each dose step-up.

Does compounded tirzepatide cause the same constipation as Zepbound? Yes. Both contain tirzepatide and act through the same dual GLP-1 and GIP receptor mechanism. The constipation risk is comparable. Common compounded additives like B12 don't meaningfully change the risk.

Can Zepbound cause bowel obstruction? Rarely. Case reports and FAERS data show bowel obstruction and ileus as rare adverse events on GLP-1 and GIP receptor agonist medications. The FDA added an ileus warning to GLP-1 labels in 2023. Severe constipation with abdominal pain, distention, or vomiting warrants urgent evaluation.

What foods help with Zepbound constipation? Berries, kiwi (2 per day has clinical-trial support for constipation), prunes (50 to 100 g per day), beans, leafy greens, oats, chia, flax. Pair high-fiber foods with adequate fluid. Olive oil at 1 to 2 tablespoons per day can also help.

Does walking help with Zepbound constipation? Yes. 20 to 30 minutes of walking per day is one of the most reliable behavioral interventions. Upright mechanical movement stimulates colonic motility. Many patients see meaningful improvement within 5 to 7 days of adding a daily walk.

Should I stop Zepbound if I get constipated? Almost never. Most constipation is manageable with the step-up protocol. About 0.3% of patients in clinical trials had constipation severe enough to discontinue. Talk with your prescriber before stopping; dose reduction or a temporary pause is usually a better option.

Sources

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
4. Zepbound prescribing information. Eli Lilly and Company. Indianapolis, IN. Revised 2024.
5. Davies MJ, et al. Effect of tirzepatide on gastric emptying. Diabetes Care. 2023;46:998-1005.
6. Sodhi M, et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330:1795-1797.
7. American College of Gastroenterology. Clinical guideline: management of chronic constipation. Am J Gastroenterol. 2021;116:17-38.
8. FDA Drug Safety Communication. GLP-1 receptor agonists and risk of ileus. U.S. Food and Drug Administration; 2023.
9. Chey WD, et al. American College of Gastroenterology guideline for the management of chronic idiopathic constipation. Am J Gastroenterol. 2021;116:17-44.
10. Rao SSC, et al. Diagnosis and treatment of slow-transit constipation. Curr Gastroenterol Rep. 2020;22:60.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. MiraLAX, Metamucil, Senokot, Dulcolax, Linzess, Amitiza, and Trulance are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.